HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tighter Testing New Normal For US OTC Sanitizer Firms Due To Contaminations During Pandemic

Executive Summary

With higher demand a norm, OTC sanitizer firms should do the same with scrutiny of their supplies of alcohol and other ingredients. “The market itself will always be much higher than a pre-COVID level as it’s a consumer product that is going to be used on a more regular basis,” says Ed Wyszumiala, head of US Pharmacopeia’s verification program.

You may also be interested in...



US Still Rinsing Out OTC Sanitizer Warnings

Of GMP warnings for OTC hand sanitizers, 114 have been submitted by FDA since pandemic began, with first sent in late April 2020, and another 12 for false COVID-19 claims, with first sent on 1 April. One GMP warning for hand sanitizer product is listed in both 2018 and 2019.

COVID-19: US Regulators Continue Enforcement, FDA Commissioner Califf Has Positive Test Results

Califf experiencing mild symptoms after testing positive for COVID-19. FDA and FTC continue finding coronavirus-related fraud in consumer health products market.

End Is Near For Distributing OTC Hand Sanitizers Manufactured Under Temporary US Guidance

The 31 March cut-off date brings to a comparatively low-profile end a well-chronicled saga of FDA acting to increase OTC hand sanitizer production as consumer demand soared in response to COVID-19.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel